Saturday 17 October 2026 Export DERM’s income statement to Excel — free account

Journey Medical Corporation

DERM Healthcare Drug Manufacturers Specialty & Generic

Journey Medical Corporation’s revenue for fiscal 2025 (year ended December 2025) was $61.9 million, up 10.2% from fiscal 2024. In the quarter to June 2026, revenue grew 23.3%, EPS grew 93.8%, free cash flow fell 84.1% and total debt rose 1.43%, each against the same quarter a year earlier.

4.97 0.16 −3.12%

Follow DERM

Alert me

Market cap: $144.7M
P/E: 0.0×
Fwd P/E: 91.8×
Dividend yield: —
F-score: 4/9
Altman Z: 1.09
Beneish M: −0.82
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 47.15%

Capital & Financial Ratios $m

Market Cap 144.65

Revenue 68.18

Net Income (6.10)

Free Cash Flow (7.49)

Net Debt (0.17)

Current Ratio 1.59

Debt/Equity 0.79

P/E ratio 0.00

Fwd P/E 91.80

P/S ratio 2.00

P/B ratio 4.26

Past 5Y EPS Growth —

This Y EPS Growth 85.64%

Next Y EPS Growth 1,096.30%

Next Y revenue growth 29.46%

Next 5Y EPS Growth (21.32%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 65.70%

10-year low 10-year high

P/B against its own 10 years 37.66%

10-year low 10-year high

EV/Sales against its own 10 years 63.88%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2020	Powerpack
2019	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	27	20	24	26
Receivables	15	10	30	36
Inventory	10	14	10	8
Other	—	—	—	—
	56	48	67	73

	2023	2024	2025	Q'26
Payables	18	16	9	8
ST’ Debt	—	—	—	5
Other	3	1	0	0
	42	35	37	46

Compound Annual Growth %

	10y	5y	3y
Sales	—	6.79%	(5.66%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	25.35%	23.32%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	16	19	—	—	—
’25	13	15	18	16	62
’24	13	15	15	14	56
’23	12	17	35	15	79
’22	23	18	16	16	74
’21	11	15	20	18	63
’20	12	9	9	—	45

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	3	(2)	—	—	—
’25	(3)	(1)	(2)	(6)	(12)
’24	(5)	(5)	(1)	2	(9)
’23	(1)	4	19	(17)	5
’22	1	(3)	(7)	(4)	(14)
’21	1	(7)	7	(3)	(2)
’20	—	—	0	5	5

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	3	(2)	—	—	—
’25	(3)	(1)	(2)	(6)	(12)
’24	(5)	(5)	(1)	(13)	(24)
’23	(6)	4	19	(17)	0
’22	(19)	(3)	(7)	(4)	(34)
’21	1	(7)	(2)	(4)	(12)
’20	—	—	(1)	5	4

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.08)	(0.01)	—	—	—
’25	(0.18)	(0.16)	(0.09)	(0.04)	(0.47)
’24	(0.53)	(0.17)	(0.12)	0.08	(0.72)
’23	(0.57)	(0.46)	0.80	(0.12)	(0.21)
’22	(0.08)	(0.43)	(0.57)	(0.60)	(1.69)
’21	0.02	(1.30)	(1.16)	(1.64)	(4.32)
’20	0.14	0.03	0.00	—	0.49

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	5.12	1.05	1.02	2.85	3.54	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	10.20	6.19	8.11	6.89	9.40
People
People	Employees	—	—	—	—	82	90	80	58	41	58
	Revenue/emp, $m	—	—	—	0.00	0.54	0.70	0.92	1.37	1.37	1.07
Income, $m
Income, $m	Revenue	—	—	—	35	45	63	74	79	56	62
	Gross margin, %	—	—	—	69.84	67.23	49.18	58.23	71.09	62.81	66.17
	EBT	—	—	—	5	7	(42)	(30)	(4)	(15)	(11)
	EBT margin, %	—	—	—	14.33	16.06	(67.10)	(40.13)	(4.59)	(26.03)	(18.38)
	Net income	—	0	—	4	5	(44)	(30)	(4)	(15)	(11)
	Depreciation	—	—	—	1	2	5	4	7	4	5
Per share, $
Per share, $	Revenue	—	—	—	3.82	4.87	6.20	4.20	4.34	2.75	2.53
	Earnings	—	—	—	0.40	0.58	(4.32)	(1.69)	(0.21)	(0.72)	(0.47)
	Cash flow	—	—	—	0.99	0.56	(0.21)	(0.77)	0.29	(0.45)	(0.51)
	Capex	—	—	—	(0.26)	(0.13)	(0.98)	(1.14)	(0.27)	(0.73)	0.00
	Free cash flow	—	—	—	0.72	0.43	(1.20)	(1.91)	0.01	(1.18)	(0.51)
	Book value	—	—	—	0.30	1.13	4.13	0.97	1.12	0.98	1.30
	Shares, m	—	—	—	9	9	10	18	18	20	24
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	1.65	1.65	0.87	0.44	1.25	1.42	3.05
	P/B	—	—	—	0.00	0.00	1.30	1.90	4.86	3.98	5.93
	EV/Sales	—	—	—	1.61	1.61	0.16	0.31	1.13	1.56	3.16
	EV/FCF	—	—	—	14.56	14.56	(0.77)	(0.69)	372.00	(3.63)	(7.13)
Cash, $m
Cash, $m	Operating cash flow	—	—	—	9	5	(2)	(14)	5	(9)	(12)
	Capex	—	—	—	(2)	(1)	(10)	(20)	(5)	(15)	0
	Free cash flow	—	—	—	7	4	(12)	(34)	0	(24)	(12)
Balance, $m
Balance, $m	Working capital	—	—	—	4	7	33	11	15	13	29
	Total debt	—	—	—	5	10	4	23	15	25	25
	Net debt	—	—	—	1	2	(45)	(9)	(13)	5	1
	Shareholders’ equity	—	—	—	3	10	42	17	20	20	32
Returns, %
Returns, %	ROA	—	—	—	21.41	12.32	(58.98)	(29.27)	(4.23)	(18.68)	(13.08)
	ROIC	—	—	—	101.01	41.33	0.00	(221.83)	(17.20)	(34.69)	(15.46)
	ROE	—	—	—	55.58	81.00	(168.12)	(100.39)	(20.64)	(72.60)	(44.03)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
AKBA Akebia Therapeutics, Inc.	$192.7M	— (loss-making)	— (loss-making)	−21.36% (below 0%: shrinking)	n/m	−88.99% (below 0%: shrinking)	78.78%	(12.88%)	Compare
DERM Journey Medical Corporation	$144.7M	— (loss-making)	91.8×	+23.33% (above 0%: growing)	n/m	−84.08% (below 0%: shrinking)	66.81%	2.46%
ORGO Organogenesis	$142.8M	— (loss-making)	— (loss-making)	−56.68% (below 0%: shrinking)	n/m	+10.29% (above 0%: growing)	45.90%	(116.54%)	Compare
CRDL Cardiol Therapeutics Inc.	$138.8M	— (loss-making)	— (loss-making)	—	n/m	+10.61% (above 0%: growing)	0.00%	0.00%	Compare
OGI Organigram Global Inc.	$131.4M	2.0×	11.4×	+49.28% (above 0%: growing)	n/m	−192.32% (below 0%: shrinking)	39.16%	5.04%	Compare
BGM BGM Group Ltd.	$114.7M	144×	44.9×	−2.59% (below 0%: shrinking)	−85.71% (below 0%: shrinking)	+3.00% (above 0%: growing)	7.12%	0.00%	Compare
PROCF Sofgen Pharma S.A	$114.0M	0.1×	4.0×	+17.28% (above 0%: growing)	n/m	+231.11% (above 0%: growing)	56.09%	36.48%	Compare
CPIX Cumberland Pharmaceuticals Inc.	$113.0M	— (loss-making)	— (loss-making)	−56.28% (below 0%: shrinking)	n/m	−82.78% (below 0%: shrinking)	100.00%	(1,898.20%)	Compare
CLVR Clever Leaves Holdings Inc.	$96.5M	— (loss-making)	— (loss-making)	+5.36% (above 0%: growing)	n/m	+70.31% (above 0%: growing)	(7.46%)	(105.91%)	Compare
Median of peers	$123.0M	2.0×	11.4×	−2.59%	—	+6.65%	42.53%	(6.44%)

All 86 Drug Manufacturers Specialty & Generic stocks →

Journey Medical Corporation (DERM) key facts

Concern: Journey Medical Corporation reported a net loss of $11.4 million, or a loss of $0.47 per share, for fiscal 2025.
Strength: Journey Medical Corporation’s revenue for fiscal 2025 (year ended December 2025) was $61.9 million, up 10.2% from fiscal 2024.
Journey Medical Corporation (DERM) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, DERM traded at $4.97, a market capitalization of $144.7 million.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 2.0× sales.
Return on equity was −44.0% and debt-to-equity 0.79.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 1.09 (distress zone) for fiscal 2025.